BioCardia, Inc. (OTCMKTS:BCDA) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07 Submission of Matters to a Vote of Security Holders.

On June 15, 2017, BioCardia, Inc. (the Company)
held its 2017 Annual Meeting of Stockholders (the Annual
Meeting). Present at the Annual Meeting in person or by
proxy were holders of 277,369,481 shares of the Companys common
stock, representing 60.603% of the voting power of the shares of
the Companys common stock as of April 21, 2017, the record date
for the Annual Meeting, and constituting a quorum for the
transaction of business. The matters before the annual meeting
are described in more detail in the Companys definitive proxy
statement filed with the United States Securities and Exchange
Commission on April 28, 2017, as amended.

Proposal 1 Election of Directors. The following nominees
were elected as Class I directors to serve until the 2020 Annual
Meeting of Stockholders and until their respective successors are
duly elected and qualified:

Proposal 2 Ratification of the Appointment of Independent
Registered Public Accounting Firm. The appointment of KPMG
LLP as the Companys independent registered public accounting firm
for its fiscal year ending December 31, 2017 was ratified.

Proposal 3 Approval of the Companys Executive
Compensation. The Companys executive compensation was
approved.

Proposal 4 Resolution Indicating how Frequently to Hold an
Advisory Vote on Executive Compensation. A frequency of
every one year for an advisory vote on executive compensation was
approved.

About BioCardia, Inc. (OTCMKTS:BCDA)

BioCardia, Inc., formerly Tiger X Medical, Inc., is a clinical-stage regenerative medicine company. The Company is engaged in developing therapeutics for cardiovascular diseases. The Company’s lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP). It focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company also offers CardiALLO Cell Therapy System (CardiALLO), an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. It focuses on the Phase II trial for CardiALLO for the treatment of ischemic systolic heart failure. The Company focuses on various fields of autologous and allogeneic cell-based therapies to manage the lives of patients with cardiovascular conditions. CardiAMP is a therapeutic treatment that includes a companion diagnostic. It consists of a cell potency screening test, a point of care cell processing platform and a biotherapeutic delivery system.